12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用 | 稀释度 |
---|---|
ELISA | 0.305-5000 ng/ml |
Adalimumab is a fully human anti–tumor necrosis factor α (anti-TNFα) monoclonal antibody that specifically blocks the interaction of TNFα with its receptors. It binds both soluble and transmembrane TNFα. It is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.
Immobilized human TNF-α at 0.5 μg/ml (50μL/well) can bind to Adalimumab with a linear range of 0.305 ng/ml to 5 μg/ml.